Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...

Madrigal Pharmaceuticals beat Q1 sales estimates with Rezdiffra, and catalysts like EU approval and pipeline plans add upside ...

CG-0416's EASL debut garnered significant attention for its rigorous preclinical validation and innovative design. The compound's ability to reprogram metabolic pathways while maintaining safety ...

The new move comes as Eli Lilly has also taken action against compounders making copies of tirzepatide, its GLP-1 and GIP agonist sold as Mounjaro for diabetes and Zepbound for obesity in the US.